Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer

Kigawa, Junzo; Minagawa, Yukihisa; Kanamori, Yasunobu; Itamochi, Hiroaki; Cheng, Xiusi; Okada, Makoto; Oishi, Tsutomu; Terakawa, Naoki

doi:10.1002/(sici)1097-0142(19980215)82:4<697::aid-cncr12>3.0.co;2-t

Cited by 54 publications

(40 citation statements)

References 15 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 However, this invaluable function is disadvantageous during chemotherapy, when enhanced detoxification by the glutathione/GST pathway may result in tumor resistance to cytotoxic agents. 20 Previous in vitro investigations and clinical studies have demonstrated that high levels of GST enzymes in tumors are associated with weaker responses to chemotherapy and poorer survival in patients with carcinomas of the breast, 21 stomach, 22 esophagus, 23 ovary, 24,25 and head and neck. 26 To our knowledge, only two studies on GSTP1 polymorphisms and breast carcinoma survival, conducted in the United States 14 and the United Kingdom, 15 respectively, have been reported to date.…”

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms in glutathione‐S‐transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

Yang

Shu

Ruan

et al. 2004

Cancer

101

View full text Add to dashboard Cite

BACKGROUNDIt has been suggested that genetic polymorphisms in certain glutathione‐S‐transferase (GST) genes reduce the effectiveness of detoxifying cytotoxins generated by chemotherapeutic agents, potentially resulting in enhanced clinical responses to chemotherapy.METHODSThe authors evaluated common polymorphisms in the GSTM1, GSTT1, and GSTP1 genes for associations with overall survival in 1034 patients with invasive breast carcinoma who were recruited into the Shanghai Breast Cancer Study between 1996 and 1998, treated with chemotherapy, and followed for a median of 5.3 years.RESULTSAfter adjusting for age, tumor stage, and the use of radiotherapy and tamoxifen, women who were homozygous for the variant GSTP1 105Val allele had a 60% reduction in mortality risk compared with women who were homozygous for the Ile allele (hazard ratio, 0.4; 95% confidence interval, 0.2–0.8). No association was found with respect to any of the GSTM1 or GSTT1 genotypes.CONCLUSIONSThe results of the current study indicate a potential role for GSTP1 polymorphism in predicting the clinical outcomes of patients with breast carcinoma who are treated with chemotherapy. Cancer 2005. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic polymorphisms in glutathione‐S‐transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

Yang

Shu

Ruan

et al. 2004

Cancer

101

View full text Add to dashboard Cite

show abstract

“…4e), hydrazones 57,138 and esters that are hydrolysed at the acidic pH found in many endosomes 137 , has become a popular strategy for intracellular drug release. Other chemistries that lend themselves to intracellular drug release include disulphide reduction 139 (FIG. 4a,b) and endosomal enzyme hydrolysis [140][141][142] (FIG.…”

Section: Self-cleaving Linkersmentioning

confidence: 99%

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Srinivasarao

Galliford

Low

2015

Nat Rev Drug Discov

566

502

View full text Add to dashboard Cite

Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumour cells through conjugation to a tumour-cell-specific small-molecule ligand, thereby reducing delivery to normal cells and the associated collateral toxicity. This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.

show abstract

“…Oxidative stress causes profound alterations of various biological structures including cellular membranes, lipids, proteins and nucleic acids. Oxidative stress is considered to be involved in aging [44][45][46][47][48][49][50][51] and in various diseases such as diabetes mellitus [52][53][54], atherosclerosis [55,56], rheumatoid arthritis [57][58][59][60], Alzheimer's disease [61][62][63], Parkinson's disease [64][65][66] and cancer [67][68][69][70][71]. There is an increasingly growing interest in identifying biomarkers for diseases in which oxidative stress is involved [72].…”

Section: Oxidative Stressmentioning

confidence: 99%

Chromatographic and mass spectrometric analysis of glutathione in biological samples

Iwasaki

Saito

Nakano

et al. 2009

Journal of Chromatography B

100

View full text Add to dashboard Cite

Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer

Abstract: Second-line chemotherapy consisting of etoposide and cisplatin is effective in the treatment of relapsed epithelial ovarian cancer. In addition, tumor concentration of GSH may be a useful predictor of the response to this therapy.

Cited by 54 publications

References 15 publications

Genetic polymorphisms in glutathione‐S‐transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

Genetic polymorphisms in glutathione‐S‐transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Chromatographic and mass spectrometric analysis of glutathione in biological samples

Contact Info

Product

Resources

About